The US Food and Drug Administration’s accelerated approval of Biogen, Inc.’s Aduhelm (aducanumab-avwa) has been the most controversial event in the Rx policy sphere – until the Centers for Medicare and Medicaid Services’ effort to essentially undo it through a national coverage determination impacting even traditional approvals of Alzheimer’s drugs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?